文献速递糖尿病

在大型社区无糖尿病队列中定义连续血糖监测的目标范围内时间

Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

基于Framingham心脏研究前瞻性队列,对血糖正常(n=560)、糖尿病前期(n=463)和糖尿病(n=152)的社区成人进行横断面分析,佩戴Dexcom G6 Pro连续血糖监测(CGM)至少7个完整日。血糖正常者70–140 mg/dL范围内时间占87.0%,平均每日超过15分钟(1.2%时间)高于180 mg/dL,约3小时/日(12.1%时间)高于140 mg/dL;糖尿病前期和糖尿病者该范围内时间分别为77.1%和46.2%。结果可为临床医生解读无糖尿病人群的CGM生理范围提供参考。

要点

  • 血糖正常成人70–140 mg/dL范围内时间平均为87.0%。
  • 血糖正常成人平均每日超过15分钟(1.2%时间)血糖高于180 mg/dL。
  • 糖尿病前期和糖尿病成人70–140 mg/dL范围内时间分别为77.1%和46.2%。

核心结论

  • 研究结果有助于理解1000余名无糖尿病参与者的生理性CGM范围,并为临床医生在CGM传感器更广泛可及于无已知糖尿病人群时提供参考。

研究设计与样本

  • Framingham心脏研究是一项前瞻性队列研究,纳入社区居住的血糖正常(n=560)、糖尿病前期(n=463)和糖尿病(n=152)成人。
  • 对佩戴Dexcom G6 Pro CGM(盲测模式)7个或以上完整日的参与者进行横断面调查。

主要发现

  • 血糖正常参与者(平均年龄58.5岁,女性64.5%,非西班牙裔白人93.3%)在70–140 mg/dL CGM范围内时间占87.0%,平均每日超过15分钟(1.2%时间)高于180 mg/dL。
  • 血糖正常参与者每日约3小时(12.1%时间)CGM血糖高于140 mg/dL。
  • 糖尿病前期和糖尿病参与者在70–140 mg/dL范围内时间分别平均为77.1%和46.2%。

临床怎么用

  • 原文未据此给出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Continuous glucose monitor (CGM) companies are beginning to market these sensors to populations without diabetes, but the range of CGM values clinicians should expect to see for this population is unclear because there have been no large studies reporting these ranges. OBJECTIVE: This work aimed to report the physiological range of CGM time in range values observed across glycemic status, including individuals without diabetes, to serve as a reference for clinicians. METHODS: The Framingham Heart Study, a prospective cohort study, was conducted among community-dwelling adults with normoglycemia (n = 560), prediabetes (n = 463), and diabetes (n = 152). We conducted a cross-sectional investigation in participants who wore a Dexcom G6 Pro CGM (in blinded mode) for 7 or more complete days. Main outcome measures included CGM metrics including mean glucose and time spent in glucose ranges. RESULTS: Normoglycemic participants (mean age 58.5 years, 64.5% women, 93.3% non-Hispanic White) spent 87.0% time in the 70 to 140 mg/dL CGM range, and, on average, more than 15 minutes/day (1.2% time) at more than 180 mg/dL. Furthermore, normoglycemic participants spent approximately 3 hours/day (12.1% time) with CGM glucose at more than 140 mg/dL. On average, participants with prediabetes and diabetes spent 77.1% and 46.2% of time in the 70 to 140 mg/dL range, respectively. CONCLUSION: Our results contribute to the understanding of the physiological CGM range in more than 1000 participants without diabetes. These results are also important for clinicians to reference as CGM sensors become more widely accessible to people without known diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Spartano NL, Sultana N, Lin H, et al. Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes. J Clin Endocrinol Metab. 2025. PMID: 39257191. doi:10.1210/clinem/dgae626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。